MindMed

MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Retrieved on: 
Thursday, December 14, 2023
Health, FDA, Neurology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Medicine, NEO, Hamilton Anxiety Rating Scale, Week, MindMed, GAD, Pharmaceutical industry, Vaccine

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced positive topline results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD).

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced positive topline results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD).
  • The Company expects that results of this study will support the advancement of MM-120 into Phase 3 clinical development for GAD.
  • MindMed management will host a conference call at 8:30 AM EST today to discuss the results of MM-120 in GAD.
  • The webcast can be accessed live here on the News & Events page in the Investors section of the MindMed website, https://mindmed.co/ .

MindMed Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Neurology, Other Health, Health, Clinical Trials, Week, Spectrum, AISRS, Congress, Prevalence, G&A, Telephone, Finance, University Hospital of Basel, Volunteering, Research, Pharmacokinetics, Growth, Attention deficit hyperactivity disorder predominantly inattentive, Clinical trial, Medicine, ECNP, Webcast, Research and development, Anticipation, European College of Neuropsychopharmacology, USD, GAD, NEO, UHB, ASD, MindMed, Patient, Administration, ADHD, Pharmaceutical industry, Birth control, Dietary supplement, Vaccine, Cryptocurrency, R

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended September 30, 2023.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended September 30, 2023.
  • Dosing is complete with topline results for the primary endpoint (Week 4) expected to be announced in Q4 2023.
  • R&D expenses were $13.2 million for the quarter ended September 30, 2023, compared to $7.8 million for the quarter ended September 30, 2022, an increase of $5.4 million.
  • MindMed management will host a conference call at 4:30 PM EST today to provide a corporate update and review the Company’s third quarter 2023 financial results.

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update

Retrieved on: 
Thursday, October 26, 2023
Biotechnology, Pharmaceutical, Health, Neurology, Telephone, NEO, Finance, MindMed, Medicine, Webcast, Pharmaceutical industry, Online shopping

ET to provide a corporate update and review the Company’s results for the quarter ended September 30, 2023.

Key Points: 
  • ET to provide a corporate update and review the Company’s results for the quarter ended September 30, 2023.
  • Individuals may participate in the live call via telephone by dialing (855) 327-6837 (domestic) or (631) 891-4304 (international).
  • The webcast can be accessed live here on the Financials page in the Investors section of the MindMed website, https://mindmed.co/ .
  • The webcast will be archived on the Company’s website for at least 30 days after the conference call.

MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

Retrieved on: 
Tuesday, October 24, 2023
Health, Neurology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, AISRS, Safety, NEO, MindMed, Medicine, ADHD, Pharmaceutical industry, Dietary supplement

“We are pleased to announce the completion of enrollment of our Phase 2a study in adults with ADHD,” said Robert Barrow, Chief Executive Officer and Director of MindMed.

Key Points: 
  • “We are pleased to announce the completion of enrollment of our Phase 2a study in adults with ADHD,” said Robert Barrow, Chief Executive Officer and Director of MindMed.
  • “This proof-of-concept trial is designed to evaluate the clinical effects of a sub-perceptual dose of MM-120 administered in a repeated fashion.
  • The study's results will inform our ongoing work to establish new clinical paradigms for this promising drug candidate.
  • Key secondary objectives, measured up to 10 weeks after the initial dose, include assessments of ADHD symptom severity, as well as safety and tolerability.

MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, CET, Attention deficit hyperactivity disorder predominantly inattentive, Social, Spectrum, Clinical trial, Research, MDMA, ASD, NEO, Medicine, MindMed, Vaccine

The Company plans to initiate its first clinical trial of MM-402 in Q4 2023.

Key Points: 
  • The Company plans to initiate its first clinical trial of MM-402 in Q4 2023.
  • This study demonstrated that administration of MM-402 increased social interaction in a characterized preclinical model of ASD.
  • MM-402 exhibited a robust effect on social interaction and was more potent than both S-MDMA and racemic MDMA with reduced hyperactivity effects.
  • “With this further preclinical evidence to support our approach, we remain on track to initiate our Phase 1 clinical trial of MM-402 later this year.”

MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

Retrieved on: 
Thursday, September 14, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, NEO, TD, Medicine, MindMed, Pharmaceutical industry, Neuropsychiatry

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that Robert Barrow, Chief Executive Officer of MindMed, will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit on Wednesday, September 20, 2023 at 11:00 a.m.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that Robert Barrow, Chief Executive Officer of MindMed, will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit on Wednesday, September 20, 2023 at 11:00 a.m.
  • ET, which is being hosted virtually.
  • The webcast of the panel discussion will be accessible to those registered to attend the summit.

MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

Retrieved on: 
Tuesday, September 12, 2023
Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, GAD, Medicine, Quality of life, Patient, NEO, Safety, MindMed, Pharmaceutical industry

“Completion of enrollment of this study is a significant milestone for MindMed and moves us one step closer to our goal of transforming the treatment of GAD for the millions suffering from the disorder,” said Robert Barrow, Chief Executive Officer and Director of MindMed.

Key Points: 
  • “Completion of enrollment of this study is a significant milestone for MindMed and moves us one step closer to our goal of transforming the treatment of GAD for the millions suffering from the disorder,” said Robert Barrow, Chief Executive Officer and Director of MindMed.
  • We anticipate sharing topline results during the fourth quarter of this year.”
    Study MMED008 is a multi-center, parallel, randomized, double-blind, placebo-controlled, dose-optimization study.
  • The trial has enrolled 198 participants who were randomized to receive a single administration of 25 µg, 50 µg, 100 µg or 200 µg of MM-120, or placebo.
  • More information about the trial is available on our website (mindmed.co), the trial’s website (anxietyresearchstudy.com) or on clinicaltrials.gov (identifier NCT05407064).

MindMed to Participate at September Investor Conferences

Retrieved on: 
Monday, August 28, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, NEO, Medicine, MindMed, Pharmaceutical industry

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:

MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures

Retrieved on: 
Monday, August 14, 2023
Neurology, Biotechnology, Pharmaceutical, Finance, General Health, Health, Professional Services, Clinical Trials, Security (finance), Partnership, Brain, NEO, Medicine, MindMed, Pharmaceutical industry

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has entered into a senior secured credit facility with K2 HealthVentures, a healthcare-focused specialty finance company.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has entered into a senior secured credit facility with K2 HealthVentures, a healthcare-focused specialty finance company.
  • “We are thrilled to announce this agreement with K2 HealthVentures, a premier partner in the life sciences industry known for strategic investments in promising healthcare companies,” said Robert Barrow, Chief Executive Officer and Director of MindMed.
  • “This transaction strengthens our balance sheet and provides us with additional operational and strategic flexibility as we enter a very exciting period for MindMed.
  • We believe in the long-term potential of MindMed’s pipeline and look forward to working with the Company to reach its critical development milestones.”
    Upon closing, $15.0 million of the $50.0 million loan facility was funded.

MindMed Reports Second Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, August 3, 2023
Biotechnology, General Health, Neurology, Health, Pharmaceutical, GAD, Anticipation, Medicine, Spectrum, Autism spectrum, Telephone, Clinical trial, ADHD, Pharmacokinetics, University Hospital of Basel, G&A, Research, Absorption, ASCP, Research and development, Attention deficit hyperactivity disorder, Patent, Patient, Administration, ASD, Annual general meeting, Webcast, Growth, Catalent, Society, NEO, Conference, Safety, MindMed, Finance, Pharmaceutical industry, Nursing, Vaccine, Cryptocurrency, UHB, R

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended June 30, 2023.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended June 30, 2023.
  • Recent Highlights and Anticipated Upcoming Milestones:
    Phase 2b study evaluating MM-120 for generalized anxiety disorder (GAD) remains on track for topline readout in Q4 2023.
  • Patient enrollment is expected to be completed by the end of Q3 2023 with topline results for the primary endpoint expected to be announced in Q4 2023.
  • MindMed management will host a conference call at 4:30 PM EST today to provide a corporate update and review the Company’s first quarter 2023 financial results.